Congestive heart failure mortality is attributable to dysrhythmic sudden death in up to 50% of cases, with the roles of amiodarone and implantable cardioverter-defibrillators continuing to evolve.
What is the evolving role of amiodarone and implantable cardioverter-defibrillators in managing ventricular dysrhythmias and sudden death mortality in patients with congestive heart failure?
This review highlights the significant contribution of sudden death to heart failure mortality and discusses the evolving therapeutic roles of amiodarone and ICDs in its management.
Congestive heart failure (CHF), one of the few cardiovascular conditions increasing in incidence and prevalence, is characterized by high morbidity and mortality. Up to 50% of the mortality is attributable to dysrhythmic sudden death. Risk stratification to identify those most susceptible to sudden death remains imperfect. The advances in CHF therapeutics and management over the past 16 years have had a favorable impact on CHF mortality including sudden death. The role of amiodarone and implantable cardioverter-defibrillator intervention is evolving and discussed in the context of current CHF management and available trials.
Leier et al. (Sat,) conducted a review in Congestive heart failure. Amiodarone and implantable cardioverter-defibrillator was evaluated. Congestive heart failure mortality is attributable to dysrhythmic sudden death in up to 50% of cases, with the roles of amiodarone and implantable cardioverter-defibrillators continuing to evolve.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: